The investigation, published in Breast Cancer Research and Treatment, was led by dermatologists and oncologists affiliated with the European Academy of Dermatology and Venereology Task Force Dermatology for Cancer Patients, with first author Ioannis-Alexios Koumprentziotis of the National and Kapodistrian University of Athens coordinating a network spanning Greece, the United Kingdom, France, Poland, and Italy. The team pursued a deliberately triangulated design. At its core sat a retrospective cohort of 56 breast cancer patients treated with sacituzumab govitecan and clinically assessed by dermatologists at participating centers. That clinical cohort was then cross-checked against two independent pharmacovigilance sources: the World Health Organization’s global adverse event database VigiBase, which contributed 696 individual case safety reports, and the French Pharmacovigilance Database, which added 46 cases. Finally, the authors reviewed the published literature from clinical trials that reported dermatologic adverse events, allowing them to compare spontaneous reporting signals with the more controlled environment of prospective trials.

Across every data source, one finding towered above the rest: alopecia, or hair loss, was by far the most frequently reported dermatologic adverse event. In the EADV clinical cohort, 41.1 percent of patients experienced it; in the French database the figure rose to 52.2 percent, and in VigiBase it reached 67.6 percent of reported cases. That gradient is itself informative, because spontaneous reporting systems tend to overrepresent dramatic or highly visible events, and few toxicities are as visible as hair loss. Behind alopecia came a consistent cluster of inflammatory and barrier-related conditions: stomatitis and mucositis, the painful ulceration of the mouth’s lining; pruritus, or generalized itching; xerosis, the abnormal dryness of the skin; and maculopapular rash, the classic raised, blotchy eruption familiar from many targeted cancer therapies. In the EADV cohort, clinicians identified 13 distinct dermatologic event types in total, a spectrum broad enough that the authors argue dermatologic monitoring should be considered a routine component of care rather than an afterthought.

The severity data are where the study delivers its most reassuring message. Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events, the standard grading scale in oncology, the researchers found that 96.4 percent of dermatologic events in the clinical cohort were grade 1 or grade 2, meaning mild to moderate. Median time to the first dermatologic event was 56 days, roughly two months into treatment, which gives clinicians a concrete window during which heightened vigilance is most useful. Most strikingly, treatment discontinuation attributable to dermatologic adverse events occurred in only 3.6 percent of patients. In other words, while skin and hair toxicity is common and can meaningfully affect quality of life, it rarely forces patients off a drug that may be extending their survival. That distinction between frequency and consequence is central to how oncologists weigh a therapy’s tolerability, and it positions sacituzumab govitecan’s cutaneous profile as manageable rather than limiting.

The pharmacovigilance arm of the study used disproportionality analysis, a statistical technique that asks whether a particular drug–event pair is reported together more often than would be expected by chance within a vast database of spontaneous reports. The standard metric here is the information component, or IC, derived from Bayesian statistics, with confidence intervals that exclude zero indicating a genuine reporting signal. In VigiBase, the analysis confirmed significant signals for alopecia, with an IC of 3.3 and a confidence interval of 3.09 to 3.53, a strong signal consistent with the drug’s known biology. Infusion-related reactions also emerged with an IC of 1.9, and stomatitis produced a signal with an IC of 1.6. These quantitative findings align neatly with the clinical cohort, a convergence the authors interpret as mutual validation: the dermatologist-assessed real-world data and the global spontaneous reporting system tell the same story about which skin toxicities matter most.

But the pharmacovigilance analysis also surfaced something the clinical cohort alone did not emphasize: a preliminary signal for cutaneous infections. Skin infections appeared among the reported events at a rate suggesting a possible association with the drug, yet the signal did not consistently meet the statistical threshold for significance across the analyses. The authors are careful not to overclaim. Spontaneous reporting databases are subject to well-known biases, including reporting bias, the notoriety effect in which newly publicized events get reported more often, and the absence of a denominator, since spontaneous systems rarely capture how many patients actually took the drug. Still, the biological plausibility is worth taking seriously. A chemotherapy payload delivered to keratinocytes can compromise the epidermal barrier, and a breached barrier is an invitation to bacterial, viral, and fungal pathogens. If the signal is real, it would represent a clinically distinct category of toxicity, one that is infectious rather than merely inflammatory, and it would argue for proactive skin care and early dermatologic consultation during treatment.

The timing of this work is not accidental. Sacituzumab govitecan is no longer a niche agent confined to heavily pretreated patients. Following positive phase 3 trials including TROPiCS-02 and EVER-132-002, and more recent evidence supporting its use in previously untreated advanced triple-negative breast cancer, the drug is moving earlier in treatment algorithms and reaching far larger patient populations. Perhaps more consequentially for the skin, it is entering combination regimens, including pairing with the immunotherapy pembrolizumab in triple-negative disease and in metastatic urothelial cancer. Combination therapy changes the toxicity calculus fundamentally: dermatologic events that are individually mild can compound, and immune checkpoint inhibitors bring their own rash and immune-mediated skin toxicities that can overlap or interact with those of an antibody–drug conjugate. The study’s authors explicitly flag this shift, arguing that structured dermatologic monitoring and prospective characterization of skin events are essential before combination regimens become routine practice.

There is also a quality-of-life dimension that the severity grading numbers understate. Recent reviews of dermatologic adverse events in oncology have emphasized that even grade 1 and 2 toxicities, alopecia chief among them, can profoundly affect body image, social functioning, and treatment adherence, particularly in a disease that disproportionately affects women. Mucositis interferes with eating and speaking; xerosis and pruritus disrupt sleep. Because these events cluster around the two-month mark of therapy, the study’s timing data offer a practical opportunity: prophylactic scalp cooling trials, early emollient regimens, and dental or oral hygiene interventions could all be timed to the period of maximal risk. The authors call for oncodermatologic management pathways precisely because the events are common enough to matter and mild enough that most patients will continue treatment through them, meaning the burden lands on supportive care rather than dose modification.

What the study cannot yet answer is mechanistic detail. The link between Trop-2 expression in keratinocytes and the observed toxicity spectrum remains an inference rather than a demonstrated pathway, and the retrospective design of the clinical cohort means that some milder events may have gone unrecorded in charts not oriented toward dermatologic detail. The authors themselves note that prospective studies with standardized dermatologic assessment would be the natural next step, ideally embedded within the ongoing combination trials that are reshaping the drug’s use. For now, the practical takeaway for clinicians is concrete: expect hair loss in a large fraction of patients, watch for stomatitis, itching, dryness, and rash beginning around eight weeks of therapy, reassure patients that severe skin toxicity is rare, and keep an open mind about cutaneous infections until the pharmacovigilance signal is either confirmed or refuted. For patients, the message is that the skin side effects of one of breast cancer’s most powerful modern drugs are, in the overwhelming majority of cases, an inconvenience to be managed rather than a reason to stop.

Subject of Research: Dermatologic adverse events associated with the antibody–drug conjugate sacituzumab govitecan in metastatic breast cancer

Article Title: Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force “Dermatology for Cancer Patients” and pharmacovigilance analysis

Article References: Koumprentziotis, I.-A., Cawley, A., Ewig, E., Gérard, A. O., Labat, M., Kamińska-Winciorek, G., Kubeczko, M., Rapparini, L., Starace, M., Grafanaki, K., Kamaratou, M., Mavroudis, D., Katoulis, A., Nikolaou, V., Heelan, K., & Koumaki, D. (2026). Dermatologic adverse events associated with Sacituzumab Govitecan: an international retrospective study from the EADV Task Force “Dermatology for Cancer Patients” and pharmacovigilance analysis. Breast Cancer Research and Treatment, 219(3), Article 24. https://doi.org/10.1007/s10549-026-08090-5

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08090-5

Keywords: sacituzumab govitecan, antibody-drug conjugate, breast cancer, dermatologic adverse events, alopecia, pharmacovigilance, VigiBase, oncodermatology, Trop-2, stomatitis, cutaneous infections, triple-negative breast cancer